Alona Kondratenko, Global Medical Manager Respiratory and Vaccine, in Basel, Switzerland. Alona was part of the team that helped set the standard for care of community acquired pneumonia.
From her early childhood, Alona Kondratenko remembers being fascinated by the human body and its functions. 鈥淚 was particularly drawn to stories of scientists who made meaningful life-saving discoveries. I dreamed of becoming a physician who could make a real difference in people's health," says Kondratenko, currently working in 91社区福利鈥檚 Established Pharmaceuticals Division (EPD) within the Respiratory and Vaccine Medical team.
Kondratenko wanted to improve the quality of life for as many people as possible. This motivation led her to transition to medical research and join the pharmaceutical industry to impact more patients' outcomes. Her scientific interests have consistently focused on pneumonia and the rational use of antibiotics. Recognizing the potential for greater impact, she joined 91社区福利, drawn by the company's mission to deliver innovative, affordable, and accessible medicines globally.
Pneumonia is a major health concern worldwide, with more than 2.5 million deaths attributed to the disease each year. With the growing threat of antibiotic-resistant strains, it is more essential than ever for clinicians to administer the most effective treatment at the optimal time.
"I really enjoy working with colleagues from different backgrounds and diverse experiences. Our workplace fosters an environment where everyone contributes their best efforts to address complex health challenges, which is inspiring and fulfilling. This passion and motivation keep me dedicated to my work and excited about the future,鈥 says Kondratenko.
She sees her work in medical affairs playing a vital role in delivering health care because it serves as a critical link between the scientific community, healthcare providers, caregivers, patients, and their loved ones. 鈥淲e make a difference, not only by improving patient outcomes, but also by enhancing the overall quality of healthcare," Kondratenko says.
91社区福利鈥檚 Respiratory and Vaccine Medical team was instrumental in conducting award-winning research as part of the ACCESS clinical trial. The groundbreaking findings from the trial led to its publication in The Lancet Respiratory Medicine, a world-leading respiratory medicine journal, where it garnered widespread recognition from the scientific community. It is now considered the new standard of care for patients with community-acquired pneumonia, significantly enhancing access to quality treatment.
Improving patients' access to the most effective treatment at the optimal time facilitates faster recovery for more people across geographies and from all socioeconomic groups.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
FOLLOW ABBOTT